203 related articles for article (PubMed ID: 25015560)
1. Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma.
Oliver JA; Ortiz R; Melguizo C; Alvarez PJ; Gómez-Millán J; Prados J
BMC Cancer; 2014 Jul; 14():511. PubMed ID: 25015560
[TBL] [Abstract][Full Text] [Related]
2. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A
J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659
[TBL] [Abstract][Full Text] [Related]
3. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
4. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
6. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
[TBL] [Abstract][Full Text] [Related]
8. O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal Cancer.
Alizadeh Naini M; Kavousipour S; Hasanzarini M; Nasrollah A; Monabati A; Mokarram P
Asian Pac J Cancer Prev; 2018 May; 19(5):1223-1227. PubMed ID: 29801405
[TBL] [Abstract][Full Text] [Related]
9. Impact of catechol-O-methyltransferase gene variants on methylation status of P16 and MGMT genes and their downregulation in colorectal cancer.
Wani HA; Majid S; Bhat AA; Amin S; Farooq R; Bhat SA; Naikoo NA; Beigh MA; Kadla SA
Eur J Cancer Prev; 2019 Mar; 28(2):68-75. PubMed ID: 30379684
[TBL] [Abstract][Full Text] [Related]
10. Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation.
Lakis NS; Brodsky AS; Karashchuk G; Audesse AJ; Yang D; Sturtevant A; Lombardo K; Wong IY; Webb AE; Anthony DC
Acta Neuropathol Commun; 2022 Nov; 10(1):159. PubMed ID: 36333778
[TBL] [Abstract][Full Text] [Related]
11. MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression.
Oliver JA; Ortiz R; Jimenez-Luna C; Cabeza L; Perazzoli G; Caba O; Mesas C; Melguizo C; Prados J
J Biosci; 2020; 45():. PubMed ID: 33097678
[TBL] [Abstract][Full Text] [Related]
12. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T
Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence.
Lee KH; Lee JS; Nam JH; Choi C; Lee MC; Park CS; Juhng SW; Lee JH
Langenbecks Arch Surg; 2011 Oct; 396(7):1017-26. PubMed ID: 21706233
[TBL] [Abstract][Full Text] [Related]
14. Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population.
Sinha R; Hussain S; Mehrotra R; Kumar RS; Kumar K; Pande P; Doval DC; Basir SF; Bharadwaj M
PLoS One; 2013; 8(4):e60142. PubMed ID: 23573237
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
16. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
[TBL] [Abstract][Full Text] [Related]
17. CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy.
Mia-Jan K; Jung SY; Kim IY; Oh SS; Choi E; Chang SJ; Kang TY; Cho MY
BMC Cancer; 2013 Mar; 13():166. PubMed ID: 23537343
[TBL] [Abstract][Full Text] [Related]
18. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity.
Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N
Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907
[TBL] [Abstract][Full Text] [Related]
19. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Wu PF; Kuo KT; Kuo LT; Lin YT; Lee WC; Lu YS; Yang CH; Wu RM; Tu YK; Tasi JC; Tseng HM; Tseng SH; Cheng AL; Lin CH
Lung Cancer; 2010 Jun; 68(3):484-90. PubMed ID: 19740564
[TBL] [Abstract][Full Text] [Related]
20. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma.
Jakob J; Hille M; Sauer C; Ströbel P; Wenz F; Hohenberger P
Radiat Oncol; 2012 Oct; 7():180. PubMed ID: 23110891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
